Pharmacotherapy Acetylcholinesterase Inhibitor Preload Failure

Pyridostigmine (Mestinon) Protocol: Vagal Activation, Preload Failure & Orthostatic Intolerance

Pyridostigmine bromide (Mestinon) has emerged as one of the most effective non-stimulant pharmacotherapies for ME/CFS and POTS. By inhibiting acetylcholinesterase, it augments parasympathetic vagal activity, enhances splanchnic and lower limb venous return, and reverses cardiac preload failure documented during invasive cardiopulmonary exercise testing (iCPET).

Clinical Pharmacotherapy Snapshot: Pyridostigmine (Mestinon)

Mechanism: Peripheral acetylcholinesterase inhibition → increased synaptic acetylcholine → parasympathetic stimulation & venous constriction.
Starting Dose: 15 mg (1/4 of a 60 mg standard tablet) once or twice daily with meals.
Target Dose Range: 30 mg to 60 mg taken 2 to 3 times daily (every 4 to 6 hours while awake).
Primary Indications: Preload failure, neuropathic POTS, delayed gastric emptying (gastroparesis), muscle fatigability.

1. Pathophysiology: Preload Failure & Vagal Ganglionic Deficit

In pioneering invasive cardiopulmonary exercise testing (iCPET) conducted by Dr. David Systrom at Brigham and Women's Hospital (Harvard Medical School), over 90% of ME/CFS and Long COVID patients were found to suffer from preload failure (PMID: 34919561).

During exertion or upright standing, venous blood pooling in the splanchnic vascular bed and lower extremities prevents adequate venous return (preload) to the right atrium. The heart is forced to contract vigorously against an underfilled chamber, precipitating low stroke volume, tachycardia, cerebral hypoperfusion, and cellular hypoxia.

How Mestinon Works: Unlike fludrocortisone or midodrine, which cause vasoconstriction or fluid retention, pyridostigmine increases acetylcholine availability at autonomic ganglia. Acetylcholine binds to postganglionic nicotinic receptors and muscarinic receptors on vascular smooth muscle, improving venous tone and propelling pooled blood back to the central circulation. Crucially, because it enhances parasympathetic tone, it attenuates orthostatic tachycardia without causing supine hypertension.

2. Dosing Protocol & Step-by-Step Titration Schedule

Patients with ME/CFS and dysautonomia often have extreme receptor hypersensitivity. Jumping immediately to standard myasthenia gravis doses (60 mg three times daily) almost always triggers severe GI cramping and treatment abandonment. Experienced autonomic clinicians recommend a cautious micro-titration:

Phase Morning Dose Mid-Day Dose Afternoon Dose Clinical Goal & Monitoring
Week 1–2 15 mg (1/4 tab) with breakfast -- -- Assess GI tolerance. Take strictly with solid food.
Week 3–4 15 mg with breakfast 15 mg with lunch -- Provides hemodynamic support across peak active day hours.
Week 5–6 30 mg (1/2 tab) 30 mg (1/2 tab) 15 mg (optional) Noticeable improvement in upright stamina and brain fog.
Maintenance 30–60 mg 30–60 mg 30–60 mg Maximum clinical benefit. Dose every 4–6 hrs. Avoid bed dosing.

3. Side Effects, Contraindications & Antidotes

Because pyridostigmine increases acetylcholine systemically, cholinergic hyperstimulation can occur:

Peer-Reviewed References

  1. Systrom DM, et al. Exercise Intolerance in Post-Acute Sequelae of COVID-19 and ME/CFS: The Role of Preload Failure and Pyridostigmine. Chest. 2022;162(4):e185-e188. PMID: 34919561.
  2. Raj SR, et al. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005;111(21):2734-2740. PMID: 15911692.
  3. Kanjwal K, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia syndrome. Am J Ther. 2011;18(2):144-148. PMID: 20087198.